Becton, Dickinson and Company

Becton, Dickinson and Company

BDXยทNYSE

$145.61

+0.82%
HealthcareMedical - Instruments & Supplies

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

At a Glance

Live Snapshot
Market Cap$52.75B
EPS5.8400
P/E Ratio24.93
Earnings Date08/06/2026

SEC Filings

BDX - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
8-K

8-K 2026

N/A

May 29, 2026
May 29, 2026
2026
8-K

8-K 2026

N/A

May 20, 2026
May 20, 2026
2026
8-K

8-K 2026

N/A

May 12, 2026
May 11, 2026
2026
8-K

8-K 2026

N/A

May 07, 2026
May 07, 2026
2026
8-K/A

8-K/A 2025 (Amended)

N/A

May 07, 2026
October 09, 2025
2025
10-Q

10-Q 2026 Q1

Q1

May 07, 2026
March 31, 2026
2026
8-K

8-K 2026

N/A

April 29, 2026
April 28, 2026
2026
8-K

8-K 2026

N/A

April 09, 2026
April 06, 2026
2026
8-K

8-K 2026

N/A

April 02, 2026
April 02, 2026
2026
8-K

8-K 2026

N/A

February 25, 2026
February 25, 2026
2026
Showing 1 to 10 of 600 filings

Understanding SEC Filings

Essential regulatory documents for investors

SEC filings are mandatory documents that publicly traded companies must submit to the Securities and Exchange Commission. These reports provide critical insights into a company's financial health, operations, risks, and strategic direction. For investors conducting due diligence, these filings are the most authoritative source of company information.

10-K

Annual Report

Comprehensive annual financial report filed within 60-90 days of fiscal year-end. Includes audited financial statements, management discussion & analysis (MD&A), risk factors, and detailed business operations. The most thorough financial disclosure of the year.

Filed annually
10-Q

Quarterly Report

Unaudited quarterly financial report filed within 40-45 days after each of the first three fiscal quarters. Provides updates on financial position, results of operations, and significant events. Essential for tracking quarterly performance trends.

Filed 3 times per year
8-K

Current Report

Event-driven filing for material events that shareholders should know about, filed within 4 business days. Includes acquisitions, executive changes, bankruptcy, earnings releases, and other significant developments. Critical for staying informed about breaking news.

Filed as events occur
DEF 14A

Proxy Statement

Definitive proxy statement sent to shareholders before annual meetings. Contains executive compensation details, board member information, voting matters, and corporate governance policies. Key for understanding management incentives and board composition.

Filed before shareholder meetings
S-1

Registration Statement

Initial registration for securities offerings, including IPOs. Provides detailed company history, business model, financial statements, risk factors, and use of proceeds. Essential for evaluating new investment opportunities and understanding company fundamentals.

Filed for new offerings
20-F

Foreign Annual Report

Annual report for foreign private issuers, equivalent to Form 10-K for non-U.S. companies. Filed within 4-6 months of fiscal year-end. Contains audited financials, business description, and regulatory disclosures adapted for international companies.

Foreign companies only

Why SEC Filings Matter

  • Regulatory Accuracy: Filings are subject to SEC review and legal penalties for misstatements, ensuring high data quality
  • Management Insights: MD&A sections reveal management's perspective on trends, challenges, and future outlook
  • Risk Assessment: Detailed risk factor disclosures help investors understand potential threats to business operations
  • Competitive Analysis: Business descriptions and segment data enable comparison with industry peers
  • Historical Context: Years of filings provide trend analysis and context for current performance